
According to Benzinga Pro data, during Q4, Epizyme (NASDAQ:EPZM) posted sales of $11.58 million. Earnings were up 23.06%, but Epizyme still reported an overall loss of $50.65 million. Epizyme collected $5.20 million in revenue during Q3, but reported earnings showed a $65.83 million loss.